Richard L. Stanfield

775 citations

38 papers · 682 indexed · h-index 16

Co-authors: Brian R. Krause Richard F. Bousley Katherine L. Hamelehle Bruce D. Roth Drago R. Sliskovic Arnold D. Essenburg Karen A. Kieft Joseph A. Picard
Topics: Cholesterol and Lipid Metabolism (27 papers)Lipoproteins and Cardiovascular Health (23 papers)Peroxisome Proliferator-Activated Receptors (12 papers)
Cited by: Biochemistry Surgery Organic Chemistry
Journals: Journal of Biological Chemistry Journal of Medicinal Chemistry Atherosclerosis
Partner nations: United States United Kingdom Russia

In The Last Decade

Richard L. Stanfield

38 papers receiving 592 citations

Peers

Countries citing papers authored by Richard L. Stanfield

Since Specialization

Citations

This map shows the geographic impact of Richard L. Stanfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard L. Stanfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard L. Stanfield more than expected).

Fields of papers citing papers by Richard L. Stanfield

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard L. Stanfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard L. Stanfield. The network helps show where Richard L. Stanfield may publish in the future.

Co-authorship network of co-authors of Richard L. Stanfield

This figure shows the co-authorship network connecting the top 25 collaborators of Richard L. Stanfield. A scholar is included among the top collaborators of Richard L. Stanfield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard L. Stanfield. Richard L. Stanfield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CI-1011 lowers lipoprotein(a) and plasma cholesterol concentrations in chow-fed cynomolgus monkeys 1998 ·Atherosclerosis ·(unknown),Mark A. Spahr,Catherine Sekerke,Richard L. Stanfield,Richard F. Bousley,Helen T. Lee,(unknown)	24
2	Inhibitors of Acyl-CoA:Cholesterol O-acyltransferase (ACAT) as hypocholesterolemic agents: Synthesis and structure-activity relationships of novel series of sulfonamides, acylphosphonamides and acylphosphoramidates 1998 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),W. Howard Roark,(unknown),Drago R. Sliskovic,Bruce D. Roth,Richard L. Stanfield,(unknown),Richard F. Bousley,Brian R. Krause	18
3	Inhibitors of acyl-CoA:cholesterol acyltransferase: novel trisubstituted ureas as hypocholesterolemic agents 1997 ·Bioorganic & Medicinal Chemistry ·(unknown),Arnold D. Essenburg,Katherine L. Hamelehle,(unknown),Ann Holmes,Brian R. Krause,Richard L. Stanfield,Bharat K. Trivedi	3
4	Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats 1996 ·Atherosclerosis ·Brian R. Krause,(unknown),Arnold D. Essenburg,Karen A. Kieft,Bruce J. Auerbach,Richard F. Bousley,Richard L. Stanfield,Roger S. Newton,C L Bisgaier	18
5	Heterocyclic Amides: Inhibitors of Acyl-CoA:Cholesterol O-Acyl Transferase with Hypocholesterolemic Activity in Several Species and Antiatherosclerotic Activity in the Rabbit 1996 ·Journal of Medicinal Chemistry ·(unknown),(unknown),Joseph A. Picard,Maureen Anderson,Sandra Bak Mueller,Thomas Bocan,Richard F. Bousley,Katherine L. Hamelehle,Brian R. Krause,Peter Lee,Richard L. Stanfield,James F. Reindel	12
6	Bioisosterism in drug design: Identification of and structure-activity relationships in a series of glycine anilide ACAT inhibitors 1995 ·Bioorganic & Medicinal Chemistry ·W. Howard Roark,Janak Padia,Gary L. Bolton,C. John Blankley,Arnold D. Essenburg,Richard L. Stanfield,Richard F. Bousley,(unknown),Bruce D. Roth	3
7	Inhibitors of acyl-coa:cholesterol acyltransferase (ACAT). 15. sulfonylurea inhibitors with excellent hypocholesterolemic activity in vivo. 1995 ·Bioorganic & Medicinal Chemistry Letters ·Bruce D. Roth,W. Howard Roark,Joseph A. Picard,Richard L. Stanfield,Richard F. Bousley,Maureen Anderson,Katherine L. Hamelehle,Reynold Homan,Brian R. Krause	7
8	Inhibitors of Acyl-CoA:Cholesterol O-Acyl Transferase (ACAT) as Hypocholesterolemic Agents. 8. Incorporation of Amide or Amine Functionalities into a Series of Disubstituted Ureas and Carbamates. Effects on ACAT Inhibition in vitro and Efficacy in vivo 1994 ·Journal of Medicinal Chemistry ·Philip O’Brien,Drago R. Sliskovic,C. John Blankley,Bruce D. Roth,(unknown),(unknown),Brian R. Krause,Richard L. Stanfield	45
9	Inhibitors of Acyl-CoA:cholesterol O-Acyl Transferase (ACAT) as Hypocholesterolemic Agents.6.The First Water-Soluble ACAT Inhibitor with Lipid-Regulating Activity 1994 ·Journal of Medicinal Chemistry ·Drago R. Sliskovic,Brian R. Krause,Joseph A. Picard,Maureen Anderson,Richard F. Bousley,Katherine L. Hamelehle,Reynold Homan,(unknown),(unknown),Richard L. Stanfield	32
10	Inhibitors of Acyl-CoA:Cholesterol Acyltransferase (ACAT). 7. Development of a Series of Substituted N-Phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with Enhanced Hypocholesterolemic Activity 1994 ·Journal of Medicinal Chemistry ·Bharat K. Trivedi,(unknown),Ann Holmes,Corinne E. Augelli‐Szafran,Arnold D. Essenburg,Katherine L. Hamelehle,Richard L. Stanfield,Richard F. Bousley,Brian R. Krause	37
11	Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase. 11. Structure-Activity Relationships of Several Series of Compounds Derived from N-(Chlorocarbonyl) Isocyanate 1994 ·Journal of Medicinal Chemistry ·Joseph A. Picard,Richard F. Bousley,Helen T. Lee,Katherine L. Hamelehle,Brian R. Krause,(unknown),Drago R. Sliskovic,Richard L. Stanfield	8
12	Comparison of lifibrol to other lipid-regulating agents in experimental animals 1994 ·Pharmacological Research ·Brian R. Krause,Richard F. Bousley,Karen A. Kieft,Donald G. Robertson,Richard L. Stanfield,(unknown),Roger S. Newton	14
13	Mechanism of cholesterol lowering in casein-fed rabbits treated with atorvastatin 1994 ·Atherosclerosis ·Bruce J. Auerbach,Richard F. Bousley,Richard L. Stanfield,Karen A. Kieft,C L Bisgaier,Brian R. Krause,Roger S. Newton	3
14	Inhibitors of acyl-CoA:cholesterol acyltransferase. 4. A novel series of urea ACAT inhibitors as potential hypocholesterolemic agents 1993 ·Journal of Medicinal Chemistry ·Bharat K. Trivedi,Ann Holmes,(unknown),C. John Blankley,W. Howard Roark,Joseph A. Picard,(unknown),Arnold D. Essenburg,Richard L. Stanfield,(unknown)	47
15	Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 2. Modification of fatty acid anilide ACAT inhibitors: bioisosteric replacement of the amide bond 1993 ·Journal of Medicinal Chemistry ·W. Howard Roark,Bruce D. Roth,Ann Holmes,Bharat K. Trivedi,Karen A. Kieft,Arnold D. Essenburg,Brian R. Krause,Richard L. Stanfield	25
16	Substituted N,N′-diphenyl ureas as potent inhibitors of acyl-CoA:Cholesterol acyltransferase (ACAT) 1993 ·Bioorganic & Medicinal Chemistry Letters ·Bharat K. Trivedi,(unknown),Richard L. Stanfield,Arnold D. Essenburg,(unknown),Brian R. Krause	4
17	Inhibitors of acyl-CoA:cholesterol acyltransferase. 5. Identification and structure-activity relationships of novel .beta.-keto amides as hypocholesterolemic agents 1993 ·Journal of Medicinal Chemistry ·Corinne E. Augelli‐Szafran,C. John Blankley,Bruce D. Roth,Bharat K. Trivedi,Richard F. Bousley,Arnold D. Essenburg,Katherine L. Hamelehle,Brian R. Krause,Richard L. Stanfield	22
18	Effect of the ACAT inhibitor CI-976 on plasma cholesterol concentrations and distribution in hamsters fed zero- and low-cholesterol diets 1992 ·Clinical Biochemistry ·(unknown),Richard F. Bousley,Karen A. Kieft,Richard L. Stanfield	51
19	Inhibitors of acyl-CoA:cholesterol acyltransferase. 1. Identification and structure-activity relationships of a novel series of fatty acid anilide hypocholesterolemic agents 1992 ·Journal of Medicinal Chemistry ·Bruce D. Roth,C. John Blankley,M. L. HOEFLE,Ann Holmes,W. Howard Roark,Bharat K. Trivedi,Arnold D. Essenburg,Karen A. Kieft,Brian R. Krause,Richard L. Stanfield	57
20	Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted-pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones 1992 ·Journal of Medicinal Chemistry ·Drago R. Sliskovic,C. John Blankley,Brian R. Krause,Roger S. Newton,(unknown),W. Howard Roark,Bruce D. Roth,Catherine Sekerke,Maxwell K. Shaw,Richard L. Stanfield	16

About Richard L. Stanfield

Richard L. Stanfield is a scholar working on Surgery, Pharmacology and Cancer Research, having authored 38 papers that have together received 682 indexed citations. Recurring topics across this work include Cholesterol and Lipid Metabolism (27 papers), Lipoproteins and Cardiovascular Health (23 papers) and Peroxisome Proliferator-Activated Receptors (12 papers). The work is most often cited by research in Biochemistry (79 citations), Surgery (359 citations) and Organic Chemistry (177 citations). Richard L. Stanfield has collaborated with scholars based in United States, United Kingdom and Russia. Frequent co-authors include Brian R. Krause, Richard F. Bousley, Katherine L. Hamelehle, Bruce D. Roth, Drago R. Sliskovic, Arnold D. Essenburg, Karen A. Kieft, Joseph A. Picard, Bharat K. Trivedi and C. John Blankley. Their work appears in journals such as Journal of Biological Chemistry, Journal of Medicinal Chemistry and Atherosclerosis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact